- AUD/USD stays on the back foot around the one-week low.
- US President Trump, Secretary of State Mike Pompeo add fuel to the US-China trade war concerns.
- Gilead’s Remdesivir will be available to the coronavirus patients this week.
- Australia’s TD Securities Inflation, Building Permits and ANZ Job Advertisements will decorate the calendar.
AUD/USD drops further towards 0.6400, currently near 0.6406, after flashing the gap-down weekly opening to 0.6413 at the start of Monday’s Asian session. In addition to the coronavirus (COVID-19), the US-China trade war fears have been the latest catalyst weighing on the market’s risk-tone sentiment.
Read: What you need to know as markets open: Pompeo and Trump ratcheted up US and China tensions
US-China fights back in motion amid tough times…
The US and China fail to keep the peace for long and jostle even amid the global crisis triggered through the coronavirus (COVID-19). US President Donald Trump initially diverted the allegations of mishandling the virus outbreak to trade deal with China. However, his recent comments were severe as they suggest an intentional act of hiding virus facts and Wuhan’s laboratory being the epicenter of the outbreak.
Also joining the show, while following the footsteps of President Trump, US Secretary of State Mike Pompeo said on ABC’s This Week, “We can confirm that the Chinese Communist Party did all that it could to make sure that the world didn't learn in a timely fashion about what was taking place.”
It should also be noted that the comments from the US policymakers are likely to be backed by the intelligence report, as per the AP, which in turn could magnify the drama.
On the other hand, Chinese news didn’t avail Friday’s off to criticize US diplomats but failed to provide any strong measures to turn down the allegations.
Also weighing on the risk-tone could be the news from Axios suggesting that the US Republican Senate Conference want to wait before passing another coronavirus stimulus package.
Not everything is negative. The positive news comes from Gilead Science where the CEO announced to donate all the supplies of the much-championed drug to combat the pandemic. The CNBC mentioned that Gilead’s Remdesivir will be available to the parents this week.
Other than the US-China trade war fears, weakness in global economics, as well as downbeat performance of Wall Street, also portrayed the risk-off sentiment on Friday.
Moving on, Aussie traders will have second-tier Inflation, housing and job numbers to take intermediate clues from. TD Securities Inflation, up for publishing at 01:00 GMT, becomes the first one to watch. The early inflation gauge will have to cross 1.5% YoY and 0.2% MoM figures for March to turn down the dovish calls for April month RBA. Following that, expected declines in March month Building Permits to -15% from 19.9% prior, coupled with ANZ Job Advertisements, prior -10.3%, could also direct near-term Aussie moves.
Technical analysis
A daily closing below the monthly ascending trend line, currently around 0.6410, becomes necessary for the bears to enter and target 0.6340 mark comprising 21-day SMA. Until then, the pair’s another attempt to challenge 100-day SMA, near 0.6565 now, can’t be ruled out.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
Gold clings to gains around $3,430
Gold fell from its previous record high of $3,500 per troy ounce, as overbought indications and a comeback in the US dollar appear to have led purchasers to take a break. Meanwhile, all eyes are on the Trump-Powell frenzy and impending Fed officials' statements.
EUR/USD trims losses, retargets 1.1500 and beyond
EUR/USD now bounces off daily troughs near 1.1460 and refocuses back on the 1.1500 barrier amid some humble knee-jerk in the US Dollar. In the meantime, markets remain cautious in light of President Trump’s criticism of Fed Chair Jerome Powell and its potential implications for the US markets.
GBP/USD treads water below 1.3400
GBP/USD is trading in a narrow zone below the 1.3400 level as the Greenback's solid comeback gains traction on Tuesday. However, continuing concerns about a US economic downturn and misgivings about the Fed's independence are anticipated to limit Cable's downside risk.
3% of Bitcoin supply in control of firms with BTC on balance sheets: The good, bad and ugly
Bitcoin disappointed traders with lackluster performance in 2025, hitting the $100,000 milestone and consolidating under the milestone thereafter. Bitcoin rallied past $88,000 early on Monday, the dominant token eyes the $90,000 level.
Five fundamentals for the week: Traders confront the trade war, important surveys, key Fed speech Premium
Will the US strike a trade deal with Japan? That would be positive progress. However, recent developments are not that positive, and there's only one certainty: headlines will dominate markets. Fresh US economic data is also of interest.
The Best brokers to trade EUR/USD
SPONSORED Discover the top brokers for trading EUR/USD in 2025. Our list features brokers with competitive spreads, fast execution, and powerful platforms. Whether you're a beginner or an expert, find the right partner to navigate the dynamic Forex market.